CD8A and myeloid sarcoma: In favor of this hypothesis, it has been demonstrated that the CD4+/CD8+ T-cell ratio is selectively reduced in the cerebrospinal fluid (CSF) but in not the peripheral blood of natalizumab patients (i.e. 0,5 under natalizumab vs 3,7 in untreated MS patients [13].